Onward Medical FIRST LOOK: Two additional BCI implants completed

Onward has successfully completed the 4th and 5th implants of its ARC-BCI brain-computer interface in two additional spinal cord injury patients. The ARC-BCI system combines Onward's ARC-IM neurostimulation platform with Clinatec's WIMAGINE BCI device to enable AI-driven, thought-controlled movement. With promising prior data on safety and signal stability, WIMAGINE is seen as a strong contender in the competitive BCI space. We reiterate our €10.4 TP and Buy rating.

Morning Notes : ATEB BB, ELI BB, CMBT BB, GREEN BB, HOMI BB, IBAB BB, ...

: ATEB BB, ELI BB, CMBT BB, GREEN BB, HOMI BB, IBAB BB, ONWD BB

Solvay SA: 1 director

A director at Solvay SA bought 2,201 shares at 30.120EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Just Eat Takeaway: tender to the offer

Following the publication of the offer memorandum yesterday by Prosus and the launch of the tender offer today until 29th July, we have withdrawn our Neutral rating and advise shareholders to tender their shares to the offer.1/ We consider the offer as generous with implied c.11.5x EV/EBITDA 2025e

Just Eat Takeaway Prosus launches offer

Following the agreement on February 24th between Prosus and JET to acquire 100% of JET shares at € 20.30ps, Prosus officially launched the all cash offer today, with the offer period starting on May 20th 2025. The offer will be declared unconditional if the acceptance reaches 95%. The 95% threshold will be reduced to 80% if the Post-offer restructuring resolutions are adopted by the AGM on July 8th 2025. These restructuring resolutions imply and asset sale and liquidation event which would resul...

Benelux Morning Notes

EVS: Weak start to the year, sales guidance maintained excluding FX, EBIT guidance low Just Eat Takeaway.com: Prosus offer launched KBC: CFO meeting – navigating above targets, strong loan growth & NII path NEPI Rockcastle: Robust Q1 results, strong top line Xior Student Housing: Dutch rent freeze not applicable to Xior

Morning Notes : EVS BB, NEXTA BB, MELE BB, TKWY NA

: EVS BB, NEXTA BB, MELE BB, TKWY NA

Benelux Morning Notes

Alfen: Dead cat bounce? Ayvens: Overhang cure. Belgian telcos: Hey! discontinues €5 offer, OBEL price increases from June 2025. B&S Group: Pulls FY EBITDA guidance in light of tariffs. D'Ieteren: CMD, 1Q25 Preview. Kendrion: Wrestling through difficult macro conditions. NN Group, ASR: Vote on Dutch pension reforms postponed. TKH Group: Not that bad, good progress at Eemshaven. UCB: US Most Favoured Nation initiative back on the agenda. Vastned: Good results, integration ongoing...

Morning Notes : ENX FP, GLPG NA, HYL BB, SOLB BB, TWEKA NA, EKOP BB, A...

: ENX FP, GLPG NA, HYL BB, SOLB BB, TWEKA NA, EKOP BB, ALFEN NA

Solvay Taking a more prudent earnings scenario, lowering target price

After a weak start of the year with a 6% decline in adjusted EBITDA in 1Q25, Solvay now expects FY25 adjusted EBITDA to land in the lower half of the previously given guidance range of € 1.0-1.1bn and we have set our new forecast close to the bottom end of this range. Weak macro conditions, which is mainly visible in soda ash, are for the moment more than offsetting the good progress with efficiency improvement measures. With current EBITDA generation, almost all FCF is absorbed to pay the high ...

Benelux Morning Notes

Talabat: 1Q25 results – delivering on its promise. TKH Group: Preview - Weak 1Q. Events Calendar

Solvay/Model update post 1Q25/BUY

Following Solvay's 1Q25 results we lower our Underlying EBITDA estimates by c.7% and our target price from €35.0 to €33.5. We maintain our BUY on the back of Solvay's attractive dividend yield of c.8% and with the c.10% share price correction following the 1Q25 results seen as overdone.

Morning Notes : AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB,...

: AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB, UCB BB, VGP BB, AUTL US, ECMPA NA

UCB FIRST LOOK: Rystiggo self-administration also approved in Japan

UCB received Japanese approval for two self-administration methods for Rystiggo (anti-FcRn) in generalised myasthenia gravis (gMG), allowing patients to use an infusion pump or manual syringe at home after training. To support the label expansion, UCB also launched a home delivery service in Japan to enhance patient convenience and satisfaction. The move aligns with Rystiggo's self-administration approval in the EU earlier this year and could support its positioning amid growing competition. We ...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 05/08/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 08/05/2025